• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Top 5 Most-Read Hemophilia Articles of 2022


The most-read hemophilia articles of the year highlighted new drug developments for hemophilia, the impact of carrier status, and opportunities for better patient education.

The top 5 most-read articles on hemophilia in 2022 explored a case study involving hemophilia A development after allogenic hematopoietic stem cell transplantation (allo-HSCT), the use of nonsteroidal anti-inflammatory drugs (NSAIDs), and more.

Here are the most read hemophilia articles of 2022.

5. Case Study Chronicles Onset and Treatment of Acquired Hemophilia A Following HSCT for ALL

Although rare, developing hemophilia A following transplantation of allo-HSCT is possible, and provides specific challenges for clinicians who need to treat AHA and preserve the transplantation graft. This article covers a case study of a 41-year-old man who developed acquired hemophilia A after allo-HSCT for acute lymphoblastic leukemia (ALL). Emicizumab and other treatments were used to help manage bleeding, retain graft function, and make sure there is no extra toxicity.

Read the full article.

4. NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed

Providers usually avoid treating patients with hemophilia with NSAIDs because of fears related to adverse bleeding or cardiovascular outcomes, even though most studies do not show this risk. Current research on NSAIDs show no statistically significant risks of bleeding or cardiovascular events, but there are limitations, and higher-quality studies as well as longer-follow up are needed.

Read the full article.

3. Review Highlights Potential of Emicizumab Prophylaxis in Acquired Hemophilia A

Treatment for hemophilia A using immunosuppressive therapy can come with difficulties like life-threatening infection and a mortality rate of 28 to 33%. Due to these outcomes, improvements in immunotherapy and hemostatic therapy are necessary. The emergence of emicizumab, a hemostatic agent, could possibly decrease the requirement for immunosuppression, but further study is necessary.

Read the full article.

2. Diagnosing and Managing Hemophilia Carriers in Thailand Stressed in New Study

Hemophilia primarily affects men whereas women are carriers because inheriting the illness is linked to an X chromosome. In Thailand, women who are hemophilia carriers face feelings such as guilt, self-blame, and stigmatization. Support is needed for women who might be carriers of hemophilia, the authors noted, as the study findings showed the importance of diagnosing carrier status for hemophilia in women and girls in Thailand.

Read the full article.

1. Systematic Approaches to Patient Educational Needs May Benefit Those With Bleeding Disorders

Although bleeding disorders like hemophilia and von Willebrand disease are rare, the education of patients with blood disorders is necessary for effective self-management. A recent study revealed that increased systematic methods are needed to evaluate needs in patient education. Nurses are frequently the professionals that these patients interact with and therefore provide an opportunity for better systematic approaches for patients with blood disorders. Further research is needed on educational interventions.

Read the full article.

Related Videos
Sarah Wall, MD
Dr Margaret Ragni Sheds Light on the Necessity of Testing Hemophilia Carriers
Steven W. Pipe, MD
Steven W. Pipe, MD
Screenshot of Ray Tancredi of Walgreens
Related Content
© 2023 MJH Life Sciences
All rights reserved.